Istiratumab
Monoclonal antibody
- none
- 1509928-04-4
- none
- XLR461MD3M
- D10943
Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.[1]
It is in development by Merrimack Pharmaceuticals and was awarded orphan drug status for pancreatic cancer.[2]
References
- ^ Alternative Names: MM-141. "Istiratumab - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
{{cite web}}
: CS1 maint: numeric names: authors list (link) - ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL : USAN (CD-106) ISTIRATUMAB" (PDF). Searchusan.ama-assn.org. Retrieved 2017-05-23.
- v
- t
- e